Skip to main content

Locally manufactured adoptive cellular therapy (ACT) product

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

  • RegistryNCT07192900
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMalignant Pleural Effusion
  • SponsorDavid Bartlett, MD
How (RIOT 4A) worksNCT071929001 min

What the film says

Read the transcript

When cancer reaches the lining of the lung, fluid collects and breathing gets harder. Drained through a catheter, that fluid is usually discarded.

The idea: that fluid is full of the patient's own T cells that already found the tumor. Grow them, and put them back.

At West Penn Hospital in Pittsburgh, the fluid goes to an on-site lab and its T cells are expanded over days, not weeks. After outpatient chemotherapy makes room, the cells return through the same catheter, with two days of low-dose interleukin-2 given locally, so the rest of the body sees little.

RIOT 4A is a first study in people, for pleural metastases or mesothelioma after standard treatment fails. David Bartlett leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07192900

    Pleural metastases / mesothelioma with effusion; symptomatic; refractory to standard care; Product made from pleural infiltrating T cells (PIT); manufactured at AHN West Penn; Short-term expansion ("Fast TIL", days not weeks); Outpatient lymphodepleting chemotherapy; single intrapleural dose via indwelling catheter (+2 more lines)

The drug

What is being tested.

Single dose, intrapleural delivery (via indwelling pleural catheter) of adoptive cellular therapy (ACT) product derived from autologous pleural infiltrating T-cells.

Low dose Interleukin-2 (IL-2) will also be administered intrapleural at the dose of 20 milliliters (mL) at 1 x 10⁵ International Units (IU)/mL starting approximately 2 hours after ACT infusion and every 8 to 16 hours thereafter, as tolerated, for up to 4 doses (total 8 x 10⁶ IU).

This is a first-in-human Phase 1 trial of short-term expanded pleural T cells to treat cancer metastatic to the pleura. Expanded cells will be delivered intrapleurally in combination with intrapleural IL-2, administered at a dose that ensures high local concentration while minimizing systemic exposure.

The study

How the trial runs.

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2).

Based on previous research it is believed that it may help fight the tumor and relieve symptoms. As a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refractory to available standard of care (SOC) therapy specific to their cancer type and must have exhausted or failed available standard of care with clinical benefit.
  • Patients will be ≥ 18 and < 80 years of age.
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), an injectable contraceptive (such as Depo-Provera), or an oral contraceptive. Active contraception should continue for at least 12 months after ACT administration. Male participants must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the preparative regimen.
  • Cardiac ejection fraction ≥ 0.45 by Multiple-Gated Acquisition (MUGA) or echocardiography.
  • No requirement for supplemental oxygen and no dyspnea immediately after effusion drainage.
  • ECOG Performance Status 0 or 1.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.